Takao S, Shinchi H, Uchikura K, Kubo M, Aikou T
First Department of Surgery, Kagoshima University School of Medicine, Japan.
Br J Surg. 1999 Mar;86(3):327-31. doi: 10.1046/j.1365-2168.1999.01018.x.
Curative resection cannot ensure long-term survival for patients with distal bile duct cancer. The aim of this study was to determine the most frequent mode of recurrence after curative resection and to analyse its risk factors.
Clinical details for 64 consecutive patients with distal bile duct cancer who underwent surgical resection between 1980 and 1997 were reviewed. Modes of recurrence and clinicopathological findings were analysed based on the residual tumour (R) classification.
The overall actuarial 5-year survival rate was 32 per cent. Of 42 patients undergoing R0 resection 10 were alive at 5 years, of 17 having R1 resection one was alive at 5 years, and none of the five patients having R2 resection survived for 5 years (R0 versus R1, P = 0.02). In the R0 group, the incidence of liver recurrence (14 of 42 patients) was similar to that in the R1 resection group (six of 17), although there were fewer lymph node and peritoneal recurrences than in patients who had R1 resection (P < 0.05). The high-risk factor for liver metastasis was microscopic vascular involvement. Important factors for survival were lymph node metastasis, microscopic vascular involvement and age. In addition, microscopic vascular involvement was the only independent factor for survival in the R0 group.
R0 resection provided significant survival benefit but had no effect on liver recurrence. Therefore, new agents or strategies to prevent liver metastasis are necessary for improvement of survival.
根治性切除并不能确保远端胆管癌患者的长期生存。本研究的目的是确定根治性切除术后最常见的复发模式并分析其危险因素。
回顾了1980年至1997年间连续接受手术切除的64例远端胆管癌患者的临床资料。根据残留肿瘤(R)分类分析复发模式和临床病理特征。
总体精算5年生存率为32%。42例行R0切除的患者中有10例存活5年,17例行R1切除的患者中有1例存活5年,5例行R2切除的患者均无存活5年者(R0与R1,P = 0.02)。在R0组中,肝复发发生率(42例患者中的14例)与R1切除组(17例患者中的6例)相似,尽管淋巴结和腹膜复发少于R1切除的患者(P < 0.05)。肝转移的高危因素是微血管侵犯。生存的重要因素是淋巴结转移、微血管侵犯和年龄。此外,微血管侵犯是R0组中唯一的独立生存因素。
R0切除提供了显著的生存益处,但对肝复发无影响。因此,需要新的药物或策略来预防肝转移以提高生存率。